ArticleUnited European gastroenterology journal2017
Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.
Article in United European gastroenterology journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma.World journal of gastroenterology · 2019Pooled it
- Review
- Metabolic comorbidities affect the survival of hepatitis B virus-related hepatocellular carcinoma in Chinese patients: a retrospective cohort study with propensity score matching.Frontiers in oncology · 2026Article
- Renin-Angiotensin Inhibitor, Captopril, Attenuates Growth of Patient-Derived Colorectal Liver Metastasis Organoids.International journal of molecular sciences · 2024Article
- Effects of renin-angiotensin inhibitors on renal function and the clinical course in patients with decompensated cirrhosis.Scientific reports · 2023Article
- The extracellular matrix in hepatocellular carcinoma: Mechanisms and therapeutic vulnerability.Cell reports. Medicine · 2023Review
- Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy.Frontiers in immunology · 2023Review
- System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.Journal of translational medicine · 2022Article
- Comprehensive Review of Hepatocellular Carcinoma in India: Current Challenges and Future Directions.JCO global oncology · 2022Review
- Tumor Vascular Remodeling Affects Molecular Dissemination to Lymph Node and Systemic Leukocytes.Tissue engineering. Part A · 2022Article
- Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation.JCI insight · 2022Article
- Captopril, a Renin-Angiotensin System Inhibitor, Attenuates Tumour Progression in the Regenerating Liver Following Partial Hepatectomy.International journal of molecular sciences · 2022Article
- Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors.European journal of cancer (Oxford, England : 1990) · 2022Article
- Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2022Review
- Article
- Angiotensin II and Angiotensin Receptors 1 and 2-Multifunctional System in Cells Biology, What Do We Know?Cells · 2021Review
- The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.Chemical reviews · 2021Review
- Irbesartan inhibits metastasis by interrupting the adherence of tumor cell to endothelial cell induced by angiotensin II in hepatocellular carcinoma.Annals of translational medicine · 2021Article
- The role of the renin-angiotensin system inhibitors in malignancy: a review.American journal of cancer research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundInhibition of the renin-angiotensin system (RAS) was associated with longer survival in patients with different solid malignancies.
objectiveThe objective of this study was to investigate the effect of RAS inhibitor (RASi) treatment (angiotensin-converting enzyme inhibitors or angiotensin-II-receptor blockers) on survival of patients with hepatocellular carcinoma (HCC).
methodsPatients diagnosed with HCC and Child-Pugh A between 1992 and 2013 who received sorafenib, experimental therapy, or best supportive care were eligible for the Vienna cohort. The Mainz cohort included patients with HCC and Child-Pugh A who received sorafenib treatment between 2007 and 2016. The association between RASi and overall survival (OS) was evaluated in univariate and multivariate analyses.
resultsIn the Vienna cohort, 43 of 156 patients received RASi for hypertension. RASi treatment was associated with longer OS (11.9 vs. 6.8 months (mo);
conclusionRAS inhibition is associated with longer survival in HCC patients with Child-Pugh class A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.